LUNG CANCER NON SMALL CELL

This early-phase trial tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding to first-line osimertinib. About 53 adults with certain genetic changes (PIK3CA/AKT1/PTEN) will rec…

This study tests a new drug, ivonescimab, alone or with chemotherapy, in 46 people with advanced non-small cell lung cancer that has specific gene changes and has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow cancer growth. Participan…

This study tests a new cell therapy called SL-28 for people with advanced solid tumors that have not responded to standard treatments. The therapy uses donor immune cells to attack the cancer. The goal is to see if it is safe and can shrink tumors in up to 60 participants with va…

This study tests whether a supervised exercise program, started before chemotherapy and continued during treatment, helps adults aged 35-65 with breast, lung, or colon cancer tolerate chemo better. The goal is to see if exercise allows patients to receive more than 85% of the pla…

This study looks at immune cells in the spit (sputum) and blood of 50 people with advanced lung cancer who are starting immunotherapy. The goal is to find patterns that show who will benefit from treatment and who might have side effects. Researchers hope this will lead to better…

This study looks at tiny particles from tumors that can be found in the blood. The goal is to learn how these markers can help diagnose cancer, predict how well treatments will work, and understand why some cancers stop responding to therapy. About 620 adults with any type of can…

This study looks at different breathing machine settings used during lung surgery (VATS) to find which one causes the fewest lung problems after surgery. About 650 adults over age 50 having lung cancer surgery will take part. The goal is to find the best way to protect the lungs …